Pulmonary vascular disease & thromboembolism
Efficacy and Safety of the Aria Pulmonary Endovascular Device in Pulmonary Hypertension
Authors' conclusion
Temporary implantation of the Aria endovascular device was feasible and safe. Device activation resulted in acute improvement of CPA and RV-PV coupling.
Study context
- Population
- Patients with pulmonary hypertension (PH) associated with left heart disease or chronic lung disease
- Participants
- 8 vs 10
- Comparison
- Aria device on vs off
- PH-LHDn = 8
- PH-CLDn = 10
- Outcome
- Incidence of serious adverse events
- Follow-up
- 30 days after the procedure
Methodological detailsDevice placed in main pulmonary artery via right femoral vein; haemodynamics assessed at baseline and with device off, on and off
- Device placed in main pulmonary artery via right femoral vein; haemodynamics assessed at baseline and with device off, on and off
Main finding
As reported in the abstract
Serious adverse events · 30 days
- No complications or investigational device-related serious adverse events
Further findings
| Outcome | PH-LHD | PH-CLD |
|---|---|---|
| Change in pulmonary arterial pulse pressure with device activationDecrease, mmHg | 5.6 (SD 4.2) | 4.2 (SD 2.2) |
| Relative change | −12% | −11% |
| P | p = 0.003 | p < 0.001 |
| Change in CPA with device activationIncrease, ml/mmHg | 0.4 (SD 0.2) | 0.4 (SD 0.3) |
| Relative change | +23% | +25% |
| P | p = 0.004 | p = 0.001 |
| Change in RV-PV coupling with device activationIncrease | 0.24 (SD 0.18) | 0.11 (SD 0.07) |
| Relative change | +40% | +21% |
| P | p = 0.012 | p = 0.001 |
Safety
Complications and device-related serious adverse events · 30 days
- No complications or investigational device-related serious adverse events occurred
Original publication
Efficacy and Safety of the Aria Pulmonary Endovascular Device in Pulmonary Hypertension. Eur J Heart Fail. Published 13 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →